Drug Profile
Research programme: immune checkpoint modulators - Eli Lilly and Company/Sanford-Burnham Medical Research Institute
Latest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; Sanford-Burnham Medical Research Institute
- Developer Eli Lilly and Company; Sanford Burnham Prebys Medical Discovery Institute
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Immunological disorders
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 28 Jun 2019 No recent reports of development identified for research development in Immunological-disorders in USA
- 14 May 2015 Early research in Autoimmune disorders in USA (unspecified route)